Avoid common mistakes on your manuscript.
Dear Sir,
We read with great interest the study by Sanchon et al. of 100 patients who underwent trans-anal total mesorectal excision (taTME) although they were neither obese (median BMI 26.9 kg/m2) nor presented with cancer of the distal third of the rectum (median distance from anal verge 7.6 cm) [1]. We would like to contribute to the external validity of the core message by adding the following comments.
We take issue with the authors’ assertion that “One of the advantages of the trans-anal route is the achievement of better oncologic results.” In fact, the meta-analysis referenced by the authors did not show improvement of the histopathology metrics of trans-anal over trans-abdominal TME [2]. Moreover, three national studies claiming oncological advantages for taTME have been found to suffer from inappropriate patient selection, statistical underpowering, or even miscalculations [3].
Regarding local recurrence rates, Sanchon et al. reported two such cases with multifocal pattern but failed to include the patient cohort that underwent trans-abdominal TME at the same institution during the same period. In fact, it is noteworthy that the Norwegian data identified an increased hazard ratio of 6.71 after Cox regression analysis [4]. Without a comparison group, the authors’ conclusion that taTME is “safe and effective” has little meaning.
Lastly, it is worrying that Sanchon et al. “did not receive any specific training in trans-anal surgery nor did they receive mentoring during the learning curve”.
Data availability
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
References
Sanchon L, Bardaji M, Labro M, Curto J, Soto C, Puig A, Pastor JC, Gómez C, Osorio A, Guariglia C, Pardo S, Vidal C, Collera P (2023) Oncological monitoring after transanal total mesorectal excision (TaTME) for rectal neoplasia. Tech Coloproctol 27:739–746. https://doi.org/10.1007/s10151-023-02755-9
Gachabayov M, Tulina I, Bergamaschi R, Tsarkov P (2019) Does transanal total mesolectal excision of rectal cancer improve histopathology metrics and/or complication rates? A meta-analysis. Surg Endosc 30:47–51. https://doi.org/10.1016/j.suronc.2019.05.012
Bendl R, Bergamaschi R (2016) Transanal TME: a bum rap? Colorectal Dis 18:7–8. https://doi.org/10.1111/codi.13231
Wasmuth HH, Faerden AE, Myklebust TA, Pfeffer F, Norderval S, Riis R, Olsen OC, Lambrecht JR, Korner H, Larsen SG (2020) Transanal total mesorectal excision for rectal cancer has been suspended in Norway. Br J Surg 107:121–130. https://doi.org/10.1002/bjs.11459
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
The article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
For this type of study formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gachabayov, M., Bergamaschi, R., Wasmuth, H. et al. Oncological monitoring after transanal total mesorectal excision for rectal neoplasia. Tech Coloproctol 27, 1411–1412 (2023). https://doi.org/10.1007/s10151-023-02866-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10151-023-02866-3